GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated May 20, 2025, serves as a transaction notification for the month of May 2025. The report discloses specific share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them, executed on May 16, 2025, on the New York Stock Exchange (XNYS).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It strictly reports on individual insider transactions involving American Depositary Shares (ADSs) with an ISIN of US37733W2044. The transaction price for all reported activities was $37.6400 per ADS.
Material Changes and Transaction Details
The filing details three distinct transactions involving dividend reinvestments within executive savings plans:
- Dr. Hal Barron (Non-Executive Director): Acquired 3,449.923 notional ADSs via the GSK Executive Supplemental Savings Plan.
- Dr. Hal Barron (Non-Executive Director): Acquired 87 ADSs via the GSK 401(k) plan.
- James Ford (SVP and Group General Counsel): Acquired 64.195 notional ADSs via the GSK Executive Supplemental Savings Plan.
All transactions were classified as initial notifications and resulted from the reinvestment of dividends rather than open market purchases.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is limited to regulatory disclosure of insider trading activity.
Key Facts for Investor Verification
- Verify the total aggregate holdings of Dr. Hal Barron and James Ford following these dividend reinvestments.
- Confirm the current market price of GSK ADSs relative to the $37.64 transaction price reported on May 16, 2025.
- Note that these transactions were automatic dividend reinvestments, not discretionary open-market purchases.
- Check for any subsequent filings regarding changes in beneficial ownership for these executives.